For example, CRISPR-mediated epigenome editing may present a novel approach for robust and long-term suppression of vascular endothelial growth factor (VEGF-A) and reversal of the AMD-related phenotype (Table 1).30 Further, CRISPRi may reversibly silence the RHO (P23H) mutant allele in adRP,17 thus providing a safer alternative to indel-mediated mutant allele disruption, which might be associated with off-target disruption of the wild-type allele. The gene discussed is VEGFA; the disease is age-related macular degeneration.